Sunday 18 October 2026
Export CYTT’s income statement to Excel — free account
Cyteir Therapeutics, Inc.
CYTT Healthcare Biotechnology
Dividend growth for five consecutive years.
3.01
0.00
0.00%
Follow CYTT
| Older periods | Dec '22 | Mar '23 | Jun '23 | Sep '23 | |
|---|---|---|---|---|---|
Current Ratio |
+8 more quarters Free account |
28.07 | 34.94 | 20.35 | 21.89 |
Net Debt/EBITDA |
14.89 | 10.34 | 14.07 | 25.54 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.79 | 0.81 | 0.49 | 1.29 | |
Capex/Depreciation |
0.00 | 1.00 | 1.42 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(0.20) | (0.28) | (0.11) | (0.13) | |
Cash per Share |
4.17 | 3.86 | 3.74 | 3.59 | |
Shareholders Equity per Share |
4.15 | 3.79 | 3.58 | 3.47 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
4.15 | 3.79 | 3.58 | 3.47 | |
Free Cash Flow |
(6.92) | (10.02) | (4.00) | (4.56) | |
Working Capital |
143.89 | 134.43 | 127.33 | 124.67 | |
Capital Expenditures |
0.00 | 0.15 | 0.15 | 0.00 | |
Net Current Asset Value |
142.26 | 134.39 | 127.31 | 124.67 | |
| Other line items | |||||
Quick Ratio |
27.68 | 34.64 | 20.31 | 21.65 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.20) | (0.29) | (0.12) | (0.13) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Payables |
1.46 | 2.09 | 2.48 | 1.09 | |
Average Assets |
174.31 | 162.47 | 154.38 | 146.35 | |
Average Common Equity |
166.79 | 154.74 | 145.79 | 139.53 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates